Odyssey Therapeutics, Inc.
Key Metrics
Market Snapshot
About
Odyssey Therapeutics, Inc. (ODTX) is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts. Incorporated in 2021, it develops medicines aimed at autoimmune and inflammatory diseases. As a company at the clinical stage, its focus is on advancing experimental treatments through testing rather than on selling approved products.
The company is building a pipeline of several candidates that target different biological pathways tied to immune and inflammatory conditions. Its lead program, OD-001, is an oral small molecule that inhibits receptor-interacting protein kinase 2 and is in a phase 2a trial for ulcerative colitis. A second candidate, OD-002, is an oral small molecule SLC15A4 inhibitor designed to block pathogenic inflammatory responses driven through TLR7, TLR8, and TLR9 and the activation of interferon regulatory factor 5. OD-003 is a protein therapeutic intended to selectively activate tumor necrosis factor receptor 2 on regulatory T cells.
Beyond these programs, the company is working on additional treatments. These include a bispecific antagonist directed at TSLP and IL-33, an oral small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, and a small molecule inhibitor of interferon regulatory factor 5. Together, the candidates reflect a strategy centered on different mechanisms within the broader area of autoimmune and inflammatory disease.
Because ODTX is in the clinical stage, its progress depends on the outcome of trials and the continued development of these candidates toward potential regulatory review. The breadth of its pipeline, spanning small molecules and protein based therapeutics across several targets, defines how Odyssey Therapeutics, Inc. pursues its goal of bringing new treatments to patients with immune driven diseases.